Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells

Fig. 1

Mutational profiling of responders and non-responders to AML-stabilizing treatment based on ATRA plus valproic acid. Primary AML cells derived from 41 patients (Additional file 1: Table S2, patients 1–2 and 15–43) were analyzed for AML-associated mutations (see Additional file 1: Table S4). The 41 patients included 12 responders and 29 non-responders to the treatment. The patient numbers at the top of the figure refer to the numbers given in Additional file 1: Table S2, and the figure presents the results only for those mutations that were detected for at least one of these patients. The classification of the mutations can be seen in the left part of the figure. The karyotype classification is given at the bottom of the figure, whereas more detailed information about the cytogenetic abnormalities are included in Additional file 1: Table S2

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us